Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | SCN4A | P35499 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29190539 | 0.84 | ALDH1A1 (0.36) | RPS6KA5ALDH1A1KDM4ELMNAGLA | |
| SCHEMBL29190621 | 0.79 | KDM4E (0.36) | ALDH1A1KDM4ELMNAGLAHPGD | |
| SCHEMBL20162224 | 0.75 | NR4A2 (0.39) | ALDH1A1KDM4ELMNAGLAHPGD | |
| SCHEMBL16061045 | 0.74 | ALDH1A1 (0.43) | RPS6KA5ALDH1A1KDM4ELMNAGLA | |
| SCHEMBL30891600 | 0.72 | RPS6KA5 (0.47) | RPS6KA5ALDH1A1KDM4EGLAHPGD | |
| SCHEMBL25551811 | 0.72 | RPS6KA5 (0.47) | RPS6KA5PIN1ADORA2AADORA1 | |
| SCHEMBL30036735 | 0.72 | RPS6KA5 (0.47) | RPS6KA5PIN1ADORA2AADORA1 | |
| SCHEMBL30936977 | 0.72 | RPS6KA5 (0.36) | RPS6KA5ALDH1A1KDM4ELMNAHPGD | |
| SCHEMBL16513320 | 0.71 | RPS6KA5 (0.43) | RPS6KA5ALDH1A1KDM4ELMNAGLA | |
| SCHEMBL20162223 | 0.71 | RPS6KA5 (0.35) | RPS6KA5ALDH1A1KDM4ELMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036715-A | 2, 4-Diarylaminopyrimidine derivative containing benzodithioryl, and pharmaceutical composition and application thereof | 盐城工业职业技术学院 | 2026-05-15 | — | — | CN | disclosed |
| EP-4382514-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2024-06-12 | — | — | EP | disclosed |
| CN-118139847-A | Pyrimidine derivatives, process for preparing the same, and pharmaceutical composition for preventing or treating cancer comprising the same as active ingredient | 韩国化学研究院 | 2024-06-04 | — | — | CN | disclosed |
| CN-113896744-B | Selective EGFR inhibitor | 成都先导药物开发股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| WO-2022139386-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 주식회사 비투에스바이오 | 2022-06-30 | — | — | WO | disclosed |
| US-10329277-B2 | N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-06-25 | — | — | US | disclosed |
| US-20180208581-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| EP-3323817-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2018-05-23 | — | — | EP | disclosed |
| US-20100144732-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. | 2010-06-10 | — | — | US | disclosed |
| CN-101563327-A | Pyrimidine kinase inhibitors | GENENTECH INC (US) | 2009-10-21 | — | — | CN | disclosed |
| EP-2099771-A1 | PYRIMIDINE KINASE INHIBITORS | Genentech, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080318989-A1 | Pyrimidine Kinase Inhibitors | GENENTECH, INC. | 2008-12-25 | — | — | US | disclosed |
| EP-1968950-A1 | PYRIMIDINE KINASE INHIBITORS | Genentech, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2008079719-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2007120339-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318989-A1 | Pyrimidine Kinase Inhibitors | DCK, DTYMK, TK1 | RPS6KA5 189/4885ALDH1A1 2990/4885KDM4E 903/4885 |
| US-20100144732-A1 | PYRIMIDINE KINASE INHIBITORS | DTYMK, DCK, TYMP | RPS6KA5 149/4885ALDH1A1 3289/4885KDM4E 687/4885 |
| US-20180208581-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | EGFR, ERBB2, ERBB3 | RPS6KA5 620/4885ALDH1A1 1216/4885KDM4E 4245/4885 |
| US-10329277-B2 | N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity | EGFR, ERBB2, ERBB3 | RPS6KA5 409/4885ALDH1A1 1263/4885KDM4E 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.